Published in Transplantation on February 01, 1992
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33
Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation (1994) 1.18
De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 1.07
Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol (1993) 1.05
Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc (1993) 1.03
Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95
One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc (1995) 0.94
History of clinical transplantation. World J Surg (2000) 0.91
Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc (1993) 0.90
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol (1994) 0.85
Role of splenectomy in human liver transplantation under modern-day immunosuppression. Dig Dis Sci (1998) 0.84
Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology (1995) 0.83
What's new in clinical solid organ transplantation by 2013. World J Transplant (2014) 0.81
Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc (1995) 0.80
Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation (1998) 0.79
Significance of semiquantitative assessment of preformed donor-specific antibody using luminex single bead assay in living related liver transplantation. Clin Dev Immunol (2013) 0.79
Current status of intestinal transplantation. Adv Surg (1994) 0.78
Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78
ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78
Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. Transplant Proc (1992) 0.77
Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76
Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc (1999) 0.76
The effect of a positive T-lymphocytotoxic crossmatch on clinical outcomes in adult-to-adult living donor liver transplantation. J Korean Surg Soc (2013) 0.75
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
"Hyperacute" renal-homograft rejection in man. N Engl J Med (1968) 3.37
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Reversal of transplantation immunity by liver grafting. Nature (1981) 3.07
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Soluble HLA antigens in the circulation of liver graft recipients. Transplantation (1989) 2.48
The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation (1984) 2.45
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38
Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation (1987) 1.31
Kupffer cells and their function. Liver (1987) 1.17
Liver allograft rejection: an overview of morphologic findings. Am J Surg Pathol (1990) 1.16
Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation (1988) 1.16
Immunopathology of liver transplantation. Crit Rev Immunol (1989) 1.15
Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunts. Am J Surg (1962) 1.09
A primate model of hyperacute renal allograft rejection. Am J Pathol (1975) 1.09
Hyperacute rejection in liver transplantation: a case report. Transplant Proc (1989) 1.07
Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation (1986) 1.01
The liver transplant waiting list--a single-center analysis. Transplantation (1991) 0.99
Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood (1981) 0.94
Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation (1988) 0.93
HLA alloimmunization and blood requirements in orthotopic liver transplantation. Transplant Proc (1989) 0.87
Delayed rejection of heart allografts in hypersensitized rats by extracorporeal donor-specific liver hemoperfusion. Transplantation (1986) 0.86
Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody. Blood (1986) 0.85
Platelet crossmatching for kidney transplants by flow cytometry. Transplantation (1989) 0.82
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 27.60
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med (1992) 8.27
The outer membrane proteins of Gram-negative bacteria: biosynthesis, assembly, and functions. Annu Rev Biochem (1978) 7.96
Urban residential environments and senior citizens' longevity in megacity areas: the importance of walkable green spaces. J Epidemiol Community Health (2002) 7.79
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Kidney transplantation under FK 506. JAMA (1990) 7.45
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol (1991) 6.30
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Green revolution: a mutant gibberellin-synthesis gene in rice. Nature (2002) 5.84
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Effects of heating in dodecyl sulfate solution on the conformation and electrophoretic mobility of isolated major outer membrane proteins from Escherichia coli K-12. J Biochem (1976) 5.52
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Identification of CRE1 as a cytokinin receptor from Arabidopsis. Nature (2001) 4.77
Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci U S A (1987) 4.72
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
DNA sequence of the gene for the outer membrane lipoprotein of E. coli: an extremely AT-rich promoter. Cell (1979) 4.31
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol (2000) 4.25
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Regulation of drought tolerance by gene manipulation of 9-cis-epoxycarotenoid dioxygenase, a key enzyme in abscisic acid biosynthesis in Arabidopsis. Plant J (2001) 3.92
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Elucidation of the Erwinia uredovora carotenoid biosynthetic pathway by functional analysis of gene products expressed in Escherichia coli. J Bacteriol (1990) 3.78
Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells (1999) 3.69
Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology (1983) 3.67
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Role of positive charge on the amino-terminal region of the signal peptide in protein secretion across the membrane. Proc Natl Acad Sci U S A (1982) 3.44
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet (1998) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Parallel neural networks for learning sequential procedures. Trends Neurosci (1999) 3.35
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Redox regulation of cellular activation. Annu Rev Immunol (1997) 3.17
Calreticulin: one protein, one gene, many functions. Biochem J (1999) 3.16
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11
Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut (2007) 3.11
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A (1995) 3.06
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98